Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the nineteen research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $125.80.
Several analysts recently issued reports on the stock. Argus assumed coverage on shares of BioNTech in a research report on Thursday, October 8th. They issued a “hold” rating for the company. Citigroup dropped their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. BMO Capital Markets downgraded BioNTech from an “outperform” rating to a “market perform” rating and cut their price target for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Morgan Stanley decreased their price objective on BioNTech from $115.00 to $114.00 and set an “overweight” rating for the company in a report on Wednesday, October 7th. Finally, Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th.
View Our Latest Report on BioNTech
BioNTech Price Performance
Shares of BNTX opened at $88.17 on Wednesday. The firm has a market cap of $22.30 billion, a PE ratio of -11.26 and a beta of 1.28. BioNTech has a 52-week low of $79.52 and a 52-week high of $124.00. The business’s 50 day moving average price is $97.24 and its two-hundred day moving average price is $97.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85.
BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million during the quarter, compared to the consensus estimate of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) EPS. The business’s revenue was down 59.5% compared to the same quarter last year. On average, equities analysts anticipate that BioNTech will post -6.62 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Ugur Sahin sold 72,000 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00. Following the completion of the sale, the chief executive officer owned 108,209 shares in the company, valued at $10,521,161.07. This represents a 39.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 807,209 shares of company stock worth $79,246,837. 19.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On BioNTech
A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of BioNTech during the 3rd quarter worth $614,000. Profund Advisors LLC raised its stake in shares of BioNTech by 12.1% in the third quarter. Profund Advisors LLC now owns 5,159 shares of the company’s stock valued at $507,000 after buying an additional 555 shares during the period. ProShare Advisors LLC grew its stake in shares of BioNTech by 5.3% during the 3rd quarter. ProShare Advisors LLC now owns 4,014 shares of the company’s stock worth $395,000 after acquiring an additional 202 shares during the period. Vise Technologies Inc. purchased a new stake in BioNTech in the 3rd quarter worth about $228,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in BioNTech by 22.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,726 shares of the company’s stock valued at $2,240,000 after acquiring an additional 4,231 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.
BioNTech Company Profile
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.
BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.
In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.
Featured Articles
- Five stocks we like better than BioNTech
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
